In addition, Be The Match BioTherapies president Amy Ronneberg has been appointed to Magenta's board of directors.
Last May, Be The Match BioTherapies announced its participation in Magenta's series B financing round and launched a strategic partnership to support the company's efforts to address significant needs across all aspects of transplant medicine.
The collaboration between Be The Match BioTherapies and Magenta leverages a wide range of Be The Match BioTherapies' assets and services, including an extensive network of transplant centers and cord blood banks, as well as expertise in research protocols, payer policy and patient education development.
Be The Match BioTherapies partners with organizations pursuing life-saving in every stage of development--from discovery through commercialization. The company provides cells consented for research, clinical or commercial use, as well as clinical trials services through its research program, the CIBMTR (Center for International Blood and Marrow Transplant Research). In addition, it has the infrastructure in place to collect patient outcomes at the time points required by regulatory authorities.
Magenta Therapeutics is developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers, and genetic diseases.
By creating a platform focused on critical areas of transplant medicine, the company is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca